electroCore, Inc. (ECOR)
electroCore, Inc. is a commercial-stage medical device company focused on developing non-invasive vagus nerve stimulation (nVNS) therapies. Its lead product, gammaCore Sapphire, is a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
Company Overview
electroCore, Inc. pioneers non-invasive vagus nerve stimulation (nVNS) therapies with gammaCore Sapphire, offering a novel, prescription-only solution for migraine and cluster headache pain, positioning them for growth in the neuromodulation market with a strong gross margin of 86.0%.
Investment Thesis
electroCore presents a compelling investment opportunity based on its innovative gammaCore Sapphire device and its potential to disrupt the migraine and cluster headache treatment market. With a gross margin of 86.0%, the company demonstrates strong pricing power and efficient cost management. The increasing adoption of non-invasive neuromodulation therapies, coupled with electroCore's focus on expanding the applications of nVNS, positions the company for significant revenue growth. Key catalysts include expanding insurance coverage for gammaCore Sapphire and successful clinical trials for new indications. While the company currently operates at a loss, reflected in its negative P/E ratio of -3.25 and a profit margin of -47.5%, the long-term growth potential and high gross margin make it an attractive investment for those seeking exposure to the medical device sector.
Key Highlights
- Market Cap of $0.04B indicates the company's current valuation in the market.
- Gross Margin of 86.0% demonstrates strong pricing power and efficient cost management.
- Beta of 0.51 suggests lower volatility compared to the overall market.
- P/E ratio of -3.25 reflects the company's current lack of profitability, but also its growth potential.
- No Dividend Yield indicates that the company is reinvesting its earnings for future growth.
Competitors
Strengths
- Innovative nVNS technology.
- High gross margin.
- Prescription-only product.
- Rechargeable and reloadable device design.
Weaknesses
- Limited product portfolio.
- Reliance on a single product for revenue.
- Negative profit margin.
- Small market capitalization.
Catalysts
- Upcoming: Clinical trial results for new indications of gammaCore Sapphire.
- Ongoing: Efforts to expand insurance coverage for gammaCore Sapphire.
- Ongoing: Expansion into new geographic markets.
- Upcoming: Potential strategic partnerships with pharmaceutical companies.
Risks
- Potential: Competition from established medical device companies with greater resources.
- Potential: Regulatory hurdles for new indications of gammaCore Sapphire.
- Ongoing: Reimbursement challenges from insurance providers.
- Potential: Product liability claims related to gammaCore Sapphire.
- Ongoing: Dependence on a single product for revenue.
Growth Opportunities
- Expanding Indications: electroCore has the opportunity to expand the use of gammaCore Sapphire beyond migraine and cluster headaches. Research into using nVNS for conditions such as post-traumatic stress disorder (PTSD) and epilepsy could open up new markets. The market size for neurological disorders is estimated to be billions of dollars, and successful clinical trials could significantly increase electroCore's revenue. Timeline for new indications is estimated within the next 3-5 years.
- Geographic Expansion: electroCore can expand its market reach by entering new geographic markets. Currently, the company's primary focus is on the United States. Expanding into Europe and Asia, where there is a growing demand for advanced medical devices, could drive significant revenue growth. The global market for medical devices is projected to reach hundreds of billions of dollars, offering a substantial opportunity for electroCore. This expansion could occur within the next 2-3 years.
- Strategic Partnerships: electroCore can form strategic partnerships with pharmaceutical companies and healthcare providers to expand its market reach and accelerate adoption of gammaCore Sapphire. Collaborating with established players in the healthcare industry can provide access to new distribution channels and customer segments. These partnerships could be established within the next year.
- Increased Insurance Coverage: Securing broader insurance coverage for gammaCore Sapphire is crucial for driving adoption and revenue growth. Working with insurance providers to demonstrate the cost-effectiveness and clinical benefits of nVNS therapy can lead to increased reimbursement rates and greater patient access. This is an ongoing effort with continuous updates.
- Direct-to-Consumer Marketing: Implementing a direct-to-consumer marketing strategy can help raise awareness of gammaCore Sapphire and drive demand. Educating patients about the benefits of nVNS therapy and providing convenient access to the device can lead to increased sales. This strategy can be implemented within the next 6-12 months.
Opportunities
- Expanding indications for nVNS therapy.
- Geographic expansion into new markets.
- Strategic partnerships with pharmaceutical companies.
- Increased insurance coverage for gammaCore Sapphire.
Threats
- Competition from established medical device companies.
- Regulatory hurdles for new indications.
- Reimbursement challenges from insurance providers.
- Potential for technological obsolescence.
Competitive Advantages
- Proprietary nVNS technology protected by patents.
- Prescription-only status creates a barrier to entry.
- Established brand recognition in the neuromodulation market.
- High gross margin demonstrates pricing power.
About
electroCore, Inc., established in 2005 and headquartered in Rockaway, New Jersey, is a commercial-stage medical device company dedicated to the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies. The company's primary focus is on providing innovative solutions for patients suffering from debilitating conditions such as migraines and cluster headaches. Their flagship product, gammaCore Sapphire, represents a significant advancement in the field of neuromodulation. It is a prescription-only, handheld device designed for the acute treatment of pain associated with migraine and episodic cluster headache in adult patients. gammaCore Sapphire is engineered for long-term use, featuring a rechargeable and reloadable design that allows for regular or intermittent therapy over many years. electroCore's commitment to innovation and patient care has positioned it as a key player in the evolving landscape of non-invasive neuromodulation, offering a potential alternative to traditional pharmaceutical interventions. With a focus on expanding the applications of nVNS therapy, electroCore is poised to address unmet needs in various therapeutic areas, solidifying its role as a leader in the medical device industry. The company operates with 73 employees.
What They Do
- Develop and commercialize non-invasive vagus nerve stimulation (nVNS) therapies.
- Offer gammaCore Sapphire, a prescription-only device for acute migraine and cluster headache pain relief.
- Provide a handheld, rechargeable device for regular or intermittent use.
- Focus on neuromodulation as an alternative to traditional pharmaceutical interventions.
- Target adult patients suffering from migraine and episodic cluster headaches.
- Offer a non-pharmacological option for pain management.
Business Model
- Sales of gammaCore Sapphire devices to patients with prescriptions.
- Revenue from device refills and accessories.
- Partnerships with healthcare providers and distributors.
- Reimbursement from insurance companies for gammaCore Sapphire treatments.
Industry Context
electroCore operates within the medical device industry, specifically in the neuromodulation segment. This segment is experiencing growth driven by increasing demand for non-invasive pain management solutions. The market for migraine and cluster headache treatments is substantial, with a growing preference for alternatives to traditional pharmaceuticals. electroCore's gammaCore Sapphire competes with products from companies like BTAI (Bioelectronic Therapeutics, Inc.), HYPD (Hyperfine, Inc.), MAIA (Maia Biotechnology, Inc.), MYO (Myomo, Inc.), and NMTC (NeuroMetrix, Inc.). The company's focus on non-invasive vagus nerve stimulation (nVNS) positions it well to capitalize on this trend.
Key Customers
- Adult patients suffering from migraine headaches.
- Adult patients suffering from episodic cluster headaches.
- Physicians who prescribe gammaCore Sapphire to their patients.
- Healthcare providers who offer gammaCore Sapphire as a treatment option.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $9M | -$3M | $0.00 |
| Q2 2025 | $7M | -$4M | $0.00 |
| Q1 2025 | $7M | -$4M | $0.00 |
| Q4 2024 | $7M | -$3M | $0.00 |
Source: Company filings
Chart & Info
Price Chart
electroCore, Inc. (ECOR) stock price: $4.73 (+0.18, +3.96%)
Why Bull
- •Recent insider buying suggests confidence in electroCore's future, indicating that key stakeholders believe in the company's potential.
- •Community sentiment has shifted positively, with discussions around the efficacy of their non-invasive therapies gaining traction.
- •Analysts are highlighting the growing interest in neuromodulation therapies, positioning electroCore favorably within a burgeoning market.
- •Recent partnerships and collaborations have sparked optimism about expanding their product reach and enhancing brand visibility.
Why Bear
- •Concerns linger over the company's revenue growth, as some investors are skeptical about the scalability of their current offerings.
- •Social sentiment reflects apprehension about regulatory hurdles that could delay product approvals and market entry.
- •There is a notable divide in community views, with some traders expressing doubts about the long-term viability of their business model.
- •Recent market developments have introduced competition, raising questions about electroCore's ability to maintain its market position.
Latest News
-
Earnings Scheduled For November 5, 2025
benzinga · Nov 5, 2025
-
Earnings Scheduled For August 6, 2025
benzinga · Aug 6, 2025
-
Earnings Scheduled For May 7, 2025
benzinga · May 7, 2025
-
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
benzinga · Jan 17, 2023
Technical Analysis
Rationale
AI-generated technical analysis for ECOR including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss electroCore, Inc. (ECOR) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for ECOR.
Make a Prediction
Set your price target for electroCore, Inc. (ECOR), choose a timeframe, and track your prediction accuracy.
Current price: $4.73
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ECOR.
Price Targets
Wall Street price target analysis for ECOR.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 8/100
Revenue grew 57.1% YoY, showing strong top-line momentum well above industry average.
-
Gross Margin 10/100
Gross margin of 86.0% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 6/100
Revenue growth is driving operating leverage, meaning profits can grow faster than costs.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates ECOR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Earnings Scheduled For November 5, 2025
Earnings Scheduled For August 6, 2025
Earnings Scheduled For May 7, 2025
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Frequently Asked Questions
What does electroCore, Inc. do?
electroCore, Inc. is a commercial-stage medical device company specializing in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies. Their primary product, gammaCore Sapphire, is a prescription-only handheld device designed for the acute treatment of pain associated with migraine and episodic cluster headache in adults. The company focuses on providing patients with a non-pharmacological alternative for pain management, utilizing neuromodulation to stimulate the vagus nerve and alleviate symptoms. electroCore's business model centers around the sale of gammaCore Sapphire devices and related accessories, targeting both patients and healthcare providers.
Is ECOR stock a good buy?
ECOR stock presents a mixed investment profile. The company's high gross margin of 86.0% indicates strong pricing power, and the potential for growth in the neuromodulation market is significant. However, the company's negative P/E ratio of -3.25 and a profit margin of -47.5% reflect its current lack of profitability. Investors should consider the potential for future growth driven by expanding indications and geographic reach, but also be aware of the risks associated with a small market capitalization and reliance on a single product. A balanced analysis suggests that ECOR may be suitable for investors with a high-risk tolerance and a long-term investment horizon.
What are the main risks for ECOR?
electroCore faces several key risks. Competition from larger, more established medical device companies poses a significant threat. Regulatory hurdles for new indications of gammaCore Sapphire could delay or prevent market expansion. Reimbursement challenges from insurance providers could limit patient access to the device. Product liability claims related to gammaCore Sapphire could negatively impact the company's financial performance. Finally, the company's dependence on a single product for revenue makes it vulnerable to changes in market demand or technological advancements.
Is ECOR a good stock to buy?
Whether ECOR is a good investment depends on your financial goals, risk tolerance, and investment horizon. Review the Investment Thesis, SWOT analysis, and Risk sections on this page. Always do your own research and consult a financial advisor before investing.
What is the ECOR MoonshotScore?
MoonshotScore is our proprietary AI-powered rating system that evaluates stocks based on growth potential, financial health, market momentum, and risk factors. It helps investors quickly identify high-potential opportunities. Check the MoonshotScore badge on this page for the current rating.
How often is ECOR data updated?
Stock prices are updated in real-time during market hours (9:30 AM - 4:00 PM ET). Company fundamentals, analyst ratings, and AI insights are refreshed daily. News is updated continuously throughout the day.
What are the growth catalysts for ECOR?
Growth catalysts vary by company and may include new product launches, market expansion, earnings surprises, partnerships, or industry tailwinds. Check the Catalysts section on this page for specific drivers relevant to electroCore, Inc..
Who are ECOR's main competitors?
electroCore, Inc.'s competitors depend on its industry and market segments. Check the Competitors section on this page for a list of direct competitors and how ECOR compares.
What do analysts say about ECOR?
Analyst ratings and price targets for ECOR are aggregated from multiple sources. Check the Analyst Consensus tab for buy/hold/sell ratings and the current consensus price target.
What is ECOR's market cap?
Market capitalization reflects the total market value of ECOR's outstanding shares. Check the Key Statistics section at the top of this page for the current market cap and other key financial metrics.
How has ECOR stock performed recently?
Check the Chart & Info tab for ECOR's recent price action, including daily, weekly, and monthly performance charts with technical indicators.
What are the risks of investing in ECOR?
Every stock carries risk. Check the Risks and Weaknesses sections on this page for ECOR-specific risk factors. Consider macroeconomic conditions, industry trends, and company-specific challenges.
Are insiders buying or selling ECOR?
Insider activity can signal management confidence. Check the Insider Flow tab for recent insider buys, sells, and exercise transactions for ECOR.
Is ECOR a good stock for beginners?
electroCore, Inc. (ECOR) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is ECOR for first-time investors?
Every stock carries risk, including electroCore, Inc. (ECOR). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like ECOR.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Financial data is based on the most recently available information.
- Future performance is subject to market conditions and company-specific factors.